Your search for tofacitinib returned 107 results

Active Filters

Click on a filter below to refine your search. Remove a filter to broaden your search.

Home remove

Your search for tofacitinib returned 107 results

Sort Results:

Relevant Recent
AIBD 2019

Tofacitinib vs Vedolizumab: Short-Term Efficacy Compared in Ulcerative Colitis

In patients with ulcerative colitis (UC), tofacitinib, a Janus kinase inhibitor, was associated with improved short-term efficacy, when compared with vedolizumab, an integrin receptor antagonist. Findings were presented at the Advances in Inflammatory Bowel Disease (AIBD) 2019 meeting in Orlando, Florida.
AIBD 2019

Impact of Tofacitinib on Extraintestinal Symptoms in UC Patients Examined

Treatment with tofacitinib appears to have little impact on extraintestinal manifestations (EIMs) in patients with moderate to severe ulcerative colitis (UC) and might even improve them, according to an analysis of the OCTAVE program. Findings were presented at the 2019 AIBD Annual Meeting in Orlando, Florida.
Safety Alerts and Recalls

Boxed Warning Added to Tofacitinib Prescribing Information

The Food and Drug Administration (FDA) has approved changes to the prescribing information for tofacitinib to include new warnings, including a Boxed Warning, regarding an increased risk of blood clots and death associated with the 10mg twice daily regimen.  The update comes after a review of data from an ongoing safety clinical trial of tofacitinib…
Musculoskeletal Disorders

Tofacitinib Benefits Sustained for Two Years in Patients With RA

The clinical benefits of tofacitinib in combination with methotrexate are sustained over 2 years among patients with rheumatoid arthritis (RA), according to a study published online January 22 in Arthritis & Rheumatology.